CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Who's worth your money for CagriSema
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 2 scored sellers
$145 · 17mg · 99.8% purity
Best value
Lowest $/mg among scored sellers
$178 · 20mg · 99.5% purity
Average price
$12.80/mg
Sellers
18
45-day trend
-2%
11 of 18 sellers have a current price· 6 stale hidden· 3 unverified hidden
Top Merit pick
🇺🇸 Profound Aminos95via Disclosed Labs · 23h ago
$8.53/mg -33.4% vs avg$145
17mg
- 🇺🇸 Simple Peptide85
via Disclosed Labs · 23h ago
$8.90/mg -30.5% vs avg$178
20mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch CagriSema
Get one email when the market actually moves — no newsletter, no noise.
About CagriSema
CAS
—
Molecular formula
—
Typical dose range
2.4 mg/week cagrilintide + 2.4 mg/week semaglutide, subcutaneous once-weekly; dose-escalation starting at 0.16 mg/week cagrilintide escalated over 16 weeks
Half-life
Cagrilintide ~184 hours (~7.7 days); semaglutide ~158 hours (~6.6 days)
COAs for CagriSema
6 third-party tests across 4 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq
Purity not on file
For
Cariintide/Semaglutide
by Certified Peptides· batch 251227CS53
20 citations indexed for CagriSema
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
Study · 2026
Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
review · 2026
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
Background Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framew…
meta-analysis · 2026
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression
Background Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
review · 2026
The 40% weight-reduction craze: market volatility, metabolic nuance, and the quest for sustainable health
The pharmaceutical industry is currently engaged in an intense competition to maximize weight reduction percentages.